THERAPEUTICS
Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia
| The first 150 words of the full text of this article appear below. |
Do antipsychotic medications differ in the ability to reduce violent behaviour in people with schizophrenia?
1493 adults with schizophrenia (DSM-IV), aged 18–65 years. Detailed inclusion and exclusion criteria are not reported in this article.
The NIMH Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project; 57 US sites (academic and community); January 2001–December 2004.
Olanzapine (7.5 mg capsule), quetiapine (200 mg capsule), risperidone (1.5 mg), perphenazine (8 mg capsule) or ziprasidone (40 mg capsule). Doses were altered according to clinical judgement, with up to 4 capsules given daily.
Primary outcome: change in violent behaviour from baseline to 6 months (MacArthur Community Violence Interview—a combined measure of minor (eg, assault without injury) and serious (eg, assault with a weapon) violent behaviours). Information was collected from both the participant and family members.
45% of participants completed 6 months of treatment and were included in the retained sample; 97% were included in the intention
New York State Psychiatric Institute/Research Foundation for Mental Hygiene, Inc, and Connecticut Department of Mental Health and Addiction Services Research Division, New York City and Hartford, Connecticut, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
